| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
Purity: ≥98%
Sennoside B is a naturally occuring anthraquinone glycoside compound isolated from Puffer fish, salamanders, frogs foot spot et al., It is a type of irritant laxative used to treat constipation and may also be used for cleaning out the intestines before a bowel examination/surgery. Sennoside B inhibits PDGF-stimulated cell proliferation. Sennoside B prevents the proliferation of cells stimulated by PDGF. Sennoside B was discovered to prevent human MG63 osteosarcoma cells from becoming phosphorylated on the PDGFR as a result of PDGF-BB. Sennoside B pre-incubation of PDGF-BB inhibited the phosphorylation of AKT, STAT-5, and ERK1/2, among other pathway components.
| Targets |
PDGFR; PDGFR
|
||
|---|---|---|---|
| ln Vitro |
Sennoside B, a type of irritant laxative extracted from rhei rhizome, binds to PDGF-BB and its receptor, inhibiting the PDGFR-beta signaling pathway, and thereby inhibiting the proliferation of MG63 cells stimulated by platelet-derived growth factor (PDGF). The phosphorylation of several pathway components, such as extracellular signal-regulated kinase 1/2 (ERK1/2), Ak strain transforming protein (AKT), and signal transducer and activator of transcription 5 (STAT-5) is inhibited when PDGF-BB is pre-incubated with sennoside B.[2] Moreover, it has an IC50 of 9 μM for bovine serum monoamine oxidase inhibition.[1]
|
||
| ln Vivo |
Sennosides were examined in a variety of toxicity investigations to assess potential risks. After a single oral dosage, acute investigations on rats and mice suggested that sennosides was only mildly toxic. Both species had LD50 values of roughly 5,000 mg/kg. Large-scale electrolyte and water loss after severe diarrhea was most likely the cause of death. No particular local or systemic toxicity was caused by sennosides in subacute studies involving rats (maximum dose/kg) and dogs (maximum dose/kg). Rat kidney weight increased slightly, but this had no toxicological significance. Sennosides were tolerated at doses up to 100 mg/kg in a 6-month study involving rats without any particular toxic effects. Secondary effects of chronic diarrhea include effects on food consumption, body weight gain, and certain biochemical parameters. It can also cause slight renal lesions. Reproduction toxicity studies and mutagenicity tests yielded normal results.
|
||
| Enzyme Assay |
Sennoside B binds to PDGF-BB and its receptor, inhibiting the PDGFR-beta signaling pathway, and thereby suppressing PDGF-stimulated cell proliferation.
|
||
| Cell Assay |
Sennoside B was either present or absent when PDGF was applied to human osteosarcoma MG63 cells. Western immunoblotting using particular antibodies against the phosphotyrosine, PDGF receptor, and downstream signaling cascade components was used to track the activation of the PDGF signaling pathway. Chromatogenic reduction of MTT was used to measure the activation of cell metabolism and proliferation.
|
||
| Animal Protocol |
|
||
| References | |||
| Additional Infomation |
Sennoside B is a member of the class of sennosides that is (9R,9'S)-9,9',10,10'-tetrahydro-9,9'-bianthracene-2,2'-dicarboxylic acid which is substituted by hydroxy groups at positions 4 and 4', by beta-D-glucopyranosyloxy groups at positions 5 and 5', and by oxo groups at positions 10 and 10'. It is a member of sennosides and an oxo dicarboxylic acid.
Sennoside B has been reported in Rheum palmatum, Rheum tanguticum, and other organisms with data available. |
| Molecular Formula |
C42H38O20
|
|
|---|---|---|
| Molecular Weight |
862.74
|
|
| Exact Mass |
862.195
|
|
| Elemental Analysis |
C, 58.47; H, 4.44; O, 37.09
|
|
| CAS # |
128-57-4
|
|
| Related CAS # |
|
|
| PubChem CID |
91440
|
|
| Appearance |
Light yellow to yellow solid powder
|
|
| Density |
1.7±0.1 g/cm3
|
|
| Boiling Point |
1144.8±65.0 °C at 760 mmHg
|
|
| Flash Point |
348.6±27.8 °C
|
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
|
| Index of Refraction |
1.763
|
|
| LogP |
1.88
|
|
| Hydrogen Bond Donor Count |
12
|
|
| Hydrogen Bond Acceptor Count |
20
|
|
| Rotatable Bond Count |
9
|
|
| Heavy Atom Count |
62
|
|
| Complexity |
1550
|
|
| Defined Atom Stereocenter Count |
12
|
|
| SMILES |
O(C1=C([H])C([H])=C([H])C2=C1C(C1C(=C([H])C(C(=O)O[H])=C([H])C=1[C@@]2([H])[C@@]1([H])C2C([H])=C(C(=O)O[H])C([H])=C(C=2C(C2C(=C([H])C([H])=C([H])C1=2)O[C@@]1([H])[C@@]([H])([C@]([H])([C@@]([H])([C@@]([H])(C([H])([H])O[H])O1)O[H])O[H])O[H])=O)O[H])O[H])=O)[C@@]1([H])[C@@]([H])([C@]([H])([C@@]([H])([C@@]([H])(C([H])([H])O[H])O1)O[H])O[H])O[H]
|
|
| InChi Key |
IPQVTOJGNYVQEO-AIFLABODSA-N
|
|
| InChi Code |
InChI=1S/C42H38O20/c43-11-23-31(47)35(51)37(53)41(61-23)59-21-5-1-3-15-25(17-7-13(39(55)56)9-19(45)27(17)33(49)29(15)21)26-16-4-2-6-22(60-42-38(54)36(52)32(48)24(12-44)62-42)30(16)34(50)28-18(26)8-14(40(57)58)10-20(28)46/h1-10,23-26,31-32,35-38,41-48,51-54H,11-12H2,(H,55,56)(H,57,58)/t23-,24-,25-,26+,31-,32-,35+,36+,37-,38-,41-,42-/m1/s1
|
|
| Chemical Name |
(9S)-9-[(9R)-2-carboxy-4-hydroxy-10-oxo-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9H-anthracen-9-yl]-4-hydroxy-10-oxo-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9H-anthracene-2-carboxylic acid
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. (2). This product is not stable in solution, please use freshly prepared working solution for optimal results. |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.90 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.90 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1591 mL | 5.7955 mL | 11.5910 mL | |
| 5 mM | 0.2318 mL | 1.1591 mL | 2.3182 mL | |
| 10 mM | 0.1159 mL | 0.5795 mL | 1.1591 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA